Galapagos

Totaal dividend boekjaar 2017: € 0,000

Slot-dividend

bedrag
€ 0,000
datum aankondiging
datum ex-dividend
datum betaling
Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

Galapagos has never declared or paid any dividends on its shares and does not expect to declare dividends in the near future. Any longer term determination to declare dividends will depend on the Galapagos' earnings, operational and financial condition, capital requirements, including for growth and acquisitions, and other factors deemed relevant by the board of directors and the shareholders. Furthermore, Galapagos' general reserve must be sufficient for any dividend payment. There can be no assurance that Galapagos will generate sufficient earnings to allow it to pay dividends. If Galapagos does generate sufficient earnings, the shareholders meeting may elect to reinvest instead of paying dividends.

Totaal dividend boekjaar 2016: € 0,000*

Slot-dividend

voorgesteld bedrag
?
datum aankondiging
apr 25, 2017
datum ex-dividend
datum betaling
Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

Galapagos has never declared or paid any dividends on its shares and does not expect to declare dividends in the near future. Any longer term determination to declare dividends will depend on the Galapagos' earnings, operational and financial condition, capital requirements, including for growth and acquisitions, and other factors deemed relevant by the board of directors and the shareholders. Furthermore, Galapagos' general reserve must be sufficient for any dividend payment. There can be no assurance that Galapagos will generate sufficient earnings to allow it to pay dividends. If Galapagos does generate sufficient earnings, the shareholders meeting may elect to reinvest instead of paying dividends.

Totaal dividend boekjaar 2015: € 0,000

Slot-dividend

bedrag
€ 0,000
datum aankondiging
datum ex-dividend
datum betaling
Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

Galapagos has never declared or paid any dividends on its shares and does not expect to declare dividends in the near future. Any longer term determination to declare dividends will depend on the Galapagos' earnings, operational and financial condition, capital requirements, including for growth and acquisitions, and other factors deemed relevant by the board of directors and the shareholders. Furthermore, Galapagos' general reserve must be sufficient for any dividend payment. There can be no assurance that Galapagos will generate sufficient earnings to allow it to pay dividends. If Galapagos does generate sufficient earnings, the shareholders meeting may elect to reinvest instead of paying dividends.

financiële events

Bedrijfsinformatie

Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

Source: company website, April 2018

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications.

We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the root cause of the disease rather than just treating the symptoms. Galapagos’ aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.

The Galapagos group, including fee-for-service subsidiairy Fidelta, has approximately 550 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France and Croatia.

Dividendbeleid

Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

Source: company website, April 2018

Galapagos has never declared or paid any dividends on its shares and does not expect to declare dividends in the near future. Any longer term determination to declare dividends will depend on the Galapagos' earnings, operational and financial condition, capital requirements, including for growth and acquisitions, and other factors deemed relevant by the board of directors and the shareholders. Furthermore, Galapagos' general reserve must be sufficient for any dividend payment. There can be no assurance that Galapagos will generate sufficient earnings to allow it to pay dividends. If Galapagos does generate sufficient earnings, the shareholders meeting may elect to reinvest instead of paying dividends.

andere bedrijven